$ELVN has been discussed by two FinTwit voices over a 12-month period from December 2025 through June 2026, generating 20 total mentions. @jacobplieth (Jacob Plieth) is the most active voice, contributing 18 mentions, while @adamfeuerstein (Adam Feuerstein ✡️) posted 2 mentions. The first mention appeared on December 9, 2025, with discussion continuing through mid-June 2026, with activity concentrated in the biotech category.

Recent discussions by @jacobplieth focus on clinical trial data and development decisions regarding Enliven Therapeutics. Posts reference the decision not to proceed with a 120mg dose formulation and critique of clinical data presentations at EHA2026, along with speculation about company capital-raising activities relative to data releases.